PATENT CLAIM ANALYSIS

Application Number: 15768025
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Claim (Index 3):
Compounds for the use according to any one of the preceding claims, wherein\n Ar is an optionally substituted mono- or bicyclic heteroaryl, forming compounds according to formula (IV) with Het-2 being\n an optionally substituted, 5- or 6-membered monocyclic heteroaryl, or \n an optionally substituted bicyclic heteroaryl, which may be fused with a ring formed by R 3  and A 2  together with the nitrogen atom to which they are bonded; and \n wherein R 1 , R 2 , Z, R 3 , A 1  and A 2  have the meaning as defined in the preceding claims.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.25532
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15769148', '14310254', '15517528', '14007533', '15185186']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7890420296431344
- 35 USC 102 Novelty (BERT): 0.5533765166821515
- Combined Prediction Score: 0.7654754783470361
- Mean Citation Score: 298.633386
- Max Citation Score: 422.5474
- Similarity Product: 327.7825493384361

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test